Molecule,Canonical SMILES,Formula,MW,Key Positives,Key Flags,Overall Assessment,#Heavy atoms,#Aromatic heavy atoms,Fraction Csp3,#Rotatable bonds,#H-bond acceptors,#H-bond donors,MR,TPSA,iLOGP,XLOGP3,WLOGP,MLOGP,Silicos-IT Log P,Consensus Log P,ESOL Log S,ESOL Solubility (mg/ml),ESOL Solubility (mol/l),ESOL Class,Ali Log S,Ali Solubility (mg/ml),Ali Solubility (mol/l),Ali Class,Silicos-IT LogSw,Silicos-IT Solubility (mg/ml),Silicos-IT Solubility (mol/l),Silicos-IT class,GI absorption,BBB permeant,Pgp substrate,CYP1A2 inhibitor,CYP2C19 inhibitor,CYP2C9 inhibitor,CYP2D6 inhibitor,CYP3A4 inhibitor,log Kp (cm/s),Lipinski #violations,Ghose #violations,Veber #violations,Egan #violations,Muegge #violations,Bioavailability Score,PAINS #alerts,Brenk #alerts,Leadlikeness #violations,Synthetic Accessibility
Quinazolinone,O=c1[nH]cnc2c1cccc2,C8H6N2O,146.15,Very soluble; good TPSA; no Lipinski violations; kinase-relevant scaffold,BBB permeant; CYP1A2 inhibition,Promising hit scaffold; CNS exposure & CYP to monitor,11,10,0,0,2,1,42.36,45.75,1.12,0.77,0.92,1.13,2.12,1.21,-1.9,1.82e+00,1.25e-02,Very soluble,-1.31,7.14e+00,4.89e-02,Very soluble,-3.21,8.95e-02,6.12e-04,Soluble,High,Yes,No,Yes,No,No,No,No,-6.64,0,2,0,0,1,0.55,0,0,1,1.39
PyrimidinylAnilide,NC(=O)c1ncncc1c1ccccc1,C11H9N3O,199.21,Balanced MW; good TPSA; high GI absorption; no CYP3A4 inhibition,Aromatic-heavy; modest solubility vs others,Acceptable hit; solubility may need tuning,15,12,0,2,3,1,55.56,68.87,1.49,1.04,1.24,0.47,1.6,1.17,-2.19,1.29e+00,6.45e-03,Soluble,-2.08,1.67e+00,8.38e-03,Soluble,-3.76,3.43e-02,1.72e-04,Soluble,High,No,No,Yes,No,No,No,No,-6.78,0,0,0,0,1,0.55,0,0,1,1.94
Imidazopyridine,c1ncc2c(c1)[nH]cn2,C6H5N3,119.12,Excellent solubility; low MW; clean ADME; no CYP inhibition,"Ghose violations (very small, polar)",Fragment-like hit; needs growth for potency,9,9,0,0,2,1,33.89,41.57,0.66,0.42,0.96,-0.25,1.67,0.69,-1.58,3.11e+00,2.61e-02,Very soluble,-0.86,1.64e+01,1.38e-01,Very soluble,-2.49,3.87e-01,3.25e-03,Soluble,High,Yes,No,No,No,No,No,No,-6.73,0,3,0,0,1,0.55,0,0,1,1.38
Thienopyrimidine,c1cnc2c(n1)csc2,C6H4N2S,136.17,Kinase-like scaffold; good permeability; no CYP risks,Ghose violations; BBB permeant,Good kinase core; CNS exposure may be undesired,9,9,0,0,2,0,37.42,54.02,1.51,0.89,1.69,0.22,2.79,1.42,-1.98,1.41e+00,1.04e-02,Very soluble,-1.61,3.35e+00,2.46e-02,Very soluble,-2.57,3.70e-01,2.72e-03,Soluble,High,Yes,No,No,No,No,No,No,-6.5,0,3,0,0,1,0.55,0,0,1,2.22
Pyrazolopyrimidine,c1ncc2c(n1)cn[nH]2,C5H4N4,120.11,Very high solubility; clean CYP profile; classic kinase hinge binder,Very small; multiple Ghose violations,Excellent starting scaffold; requires expansion,9,9,0,0,3,1,31.68,54.46,0.49,-0.08,0.35,-0.67,1.23,0.26,-1.27,6.39e+00,5.32e-02,Very soluble,-0.61,2.94e+01,2.44e-01,Very soluble,-2.12,9.17e-01,7.64e-03,Soluble,High,No,No,No,No,No,No,No,-7.09,0,3,0,0,1,0.55,0,0,1,1.29
IndazoleCarboxamide,NC(=O)C1=NN=C2C1C=CC=C2,C8H7N3O,161.16,High solubility; good TPSA; strong hinge-binding motif,Higher synthetic accessibility; polar,Strong hit candidate; chemically tractable,12,0,0.12,1,3,1,52.32,67.81,0.33,0.18,-0.74,-0.14,0.98,0.12,-0.89,2.09e+01,1.30e-01,Very soluble,-1.16,1.11e+01,6.89e-02,Very soluble,-0.3,8.11e+01,5.04e-01,Soluble,High,No,No,No,No,No,No,No,-7.16,0,2,0,0,1,0.55,0,0,1,3.88
